K
Kiran Khandke
Researcher at Pfizer
Publications - 26
Citations - 1275
Kiran Khandke is an academic researcher from Pfizer. The author has contributed to research in topics: Calicheamicin & Oncofetal antigen. The author has an hindex of 13, co-authored 25 publications receiving 1152 citations.
Papers
More filters
Journal ArticleDOI
Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies
John F. DiJoseph,Douglas Armellino,Erwin R. Boghaert,Kiran Khandke,Maureen Dougher,Latha Sridharan,Arthur Kunz,Hamann Philip Ross,Boris Gorovits,Chandrasekhar Udata,Justin Keith Moran,Andrew George Popplewell,Sue Stephens,Philip Frost,Nitin K. Damle +14 more
TL;DR: CD22-targeted delivery of CalichDMH is a potent and effective preclinical therapeutic strategy for BCLs and the strong antitumor profile of CMC-544 supports its clinical evaluation as a treatment option for B-lymphoid malignancies.
Journal ArticleDOI
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments
Frank Loganzo,Xingzhi Tan,Matthew Sung,Guixian Jin,Jeremy S. Myers,Eugene Melamud,Fang Wang,Veronica Diesl,Maximillian T. Follettie,Sylvia Musto,My-Hanh Lam,William T. Hu,Manoj Charati,Kiran Khandke,Kenny Sung Kyoo Kim,Mike Cinque,Judy Lucas,Edmund I. Graziani,Andreas Maderna,Christopher J. O’Donnell,Kim Arndt,Hans-Peter Gerber +21 more
TL;DR: In this article, a trastuzumab-maytansinoid ADC (TM-ADC) was applied to breast cancer cell lines, and the authors found that the ADC-resistant cells, 361-TM and JIMT1-TM, were characterized by cytotoxicity, proteomic, transcriptional and other profiling.
Journal ArticleDOI
Long-term Tumor Regression Induced by an Antibody–Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells
Puja Sapra,Marc Damelin,John F. DiJoseph,Kimberly Ann Marquette,Kenneth G. Geles,Jonathan Golas,Maureen Dougher,Bitha Narayanan,Andreas Giannakou,Kiran Khandke,Russell Dushin,Elana Ernstoff,Judy Lucas,Mauricio Leal,George Hu,Christopher J. O’Donnell,Lioudmila Tchistiakova,Robert T. Abraham,Hans-Peter Gerber +18 more
TL;DR: In this article, an anti-5T4 ADC (A1mcMMAF) was developed by sulfydryl-based conjugation of the humanized A1 antibody to the tubulin inhibitor monomethylauristatin F via a maleimidocaproyl linker.
Patent
Antibody-drug conjugates
Hans-Peter Gerber,John F. DiJoseph,Kiran Khandke,Kimberly Ann Marquette,Puja Sapra,Lioudmila Tchistiakova +5 more
TL;DR: In this paper, the anti-5T4 antibody drug conjugates and methods for preparing and using the same are discussed and discussed. But the methods for using the conjugate are not discussed.
Journal ArticleDOI
Antibody-Targeted Chemotherapy with the Calicheamicin Conjugate hu3S193-N-Acetyl γ Calicheamicin Dimethyl Hydrazide Targets Lewisy and Eliminates Lewisy-Positive Human Carcinoma Cells and Xenografts
Erwin R. Boghaert,Latha Sridharan,Douglas Armellino,Kiran Khandke,John F. DiJoseph,Arthur Kunz,Maureen Dougher,Fan Jiang,Lyka B. Kalyandrug,Hamann Philip Ross,Philip Frost,Nitin K. Damle +11 more
TL;DR: Hu3S193-CalichDMH can specifically eliminate Ley+ tumors and these results support development of this conjugate for treatment of carcinomas.